Sam Lessin

Sam Lessin, Co-founder and General Partner of Slow Ventures, previously VP of Product at Facebook, shares riveting insights on AI and venture capital. He argues that AI is overhyped compared to the disruptive potential of crypto. Lessin also discusses a radical shift in the venture capital landscape towards bespoke funding strategies. Additionally, he highlights his efforts to promote meritocracy and innovative hiring practices at Meritfirst, focusing on unlocking hidden talent and reforming traditional structures in corporate America.

Zach Weinberg, a healthcare tech mogul and co-founder of Flatiron Health, joins a powerhouse lineup of tech experts including Stephen Balaban of Lambda, AI investor Leigh Marie Braswell, and nuclear innovator Doug Bernauer. They explore the ups and downs of AI, dissect Apple’s struggles, and delve into exciting advancements in nuclear energy. There’s also a compelling discussion on the latest trends in biotech and the importance of regulatory shifts in energy solutions. Together, these innovators illuminate the future of technology and its impact on society.

Sam Lessin, a General Partner at Slow Ventures, shares insights on the evolving aspirations of startup founders in the booming AI landscape. Jon Sakoda from Decibel dives into the competitive AI investment scene, highlighting the importance of data in the current market. Ron Miasnik, a new partner at Bain Capital Ventures, discusses the rise of AI in traditional industries, especially within Israel's dynamic startup ecosystem. Together, they unpack the shifts in venture capital strategies and the implications of these trends for the future of investments.

Sam Lessin, a Partner at Slow Ventures and former Facebook VP, shares invaluable insights shaped by his father's wisdom. He emphasizes the '4:30 AM Advantage', advocating for early starts to gain a competitive edge. Lessin discusses the significance of joy as a sustainable asset in business, stating that angry people rarely win. He also introduces 'Type Two Fun', highlighting how enduring challenges builds resilience. Plus, he recounts a remarkable investment journey in Solana, underscoring the value of relationships in success.

Jacob Kimmel, co-founder and president of New Limit, dives into the revolutionary world of longevity medicine, exploring the future of epigenetic reprogramming and its potential to enhance health and lifespan. Sam Lessin of Slow Ventures shares insights on OpenAI's competitive hiring platform, discussing the evolving skills needed in entrepreneurship and the tech landscape. The conversation also touches on the rising popularity of GLP-1 medications in Silicon Valley, highlighting not just weight loss benefits but broader lifestyle impacts, all set against the backdrop of the shifting enterprise software market.